Clinical Trials
31 articles on Clinical Trials, written by Shotlee and medically reviewed for clinical accuracy.
Retatrutide Breaks Records: What Phase 3 TRIUMPH-1 Data Means
Eli Lilly's Retatrutide has shown remarkable weight loss potential in Phase 3 trials. We break down the TRIUMPH-1 results, safety data, and what patients can expect.
9 min read
Retatrutide Trials: Why Extreme Weight Loss Isn't Always Safe
Clinical trials for the triple-agonist Retatrutide show promising weight loss, but 11% of high-dose participants dropped out due to side effects.
7 min read
The Next Wave of Weight Loss: Understanding Oral GLP-1 Therapy
The landscape of chronic weight management is rapidly evolving beyond injectable GLP-1 medications. New research, including trials for the oral, non-peptide drug orforglipron, suggests a future where highly effective weight loss treatment is as simple as taking a daily pill, potentially overcoming barriers of cost and injection fatigue.
6 min read
GLP-1 Drugs for Alcohol Use Disorder: The Future of Addiction Treatment?
GLP-1 receptor agonists, widely known for their efficacy in weight management and type 2 diabetes, are showing remarkable promise in addressing Alcohol Use Disorder (AUD). Emerging research suggests these injectable therapies may fundamentally alter the brain's reward pathways, offering a novel pharmaceutical path for those struggling with heavy drinking.
6 min read
GLP-1 Agonists for Psoriasis: New Hope for Weight & Inflammation
A comprehensive guide to the National Psoriasis Foundation's findings on GLP-1 receptor agonists as adjunct therapy for psoriasis, including trial data and monitoring strategies.
9 min read
Survodutide Shines: Dual GLP-1/Glucagon Agonist Shows Major Weight Loss
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.
7 min read
Arecor CEO on FY25 Highlights: AT278 & GLP-1 Progress
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
4 min read
Fake Retatrutide Weight Loss Drug Flooding Online Market
Counterfeit versions of retatrutide, a promising but unapproved weight loss drug, are flooding online markets despite ongoing phase 3 clinical trials. Experts like obesity specialist Samantha Hocking highlight its potential for 29% body weight loss by targeting GLP-1, GIP, and glucagon. However, doctors and Eli Lilly warn of serious risks from these fake products.
5 min read
Cheaper Generic Semaglutide in India: Experts Warn Against Quick-Fix Use
Cheaper generic semaglutide is transforming access to weight loss and diabetes treatment in India, priced at just Rs750 per weekly injection. However, experts caution against 'quick-fix' use without medical oversight, highlighting risks like 40% muscle loss from lean mass. Discover clinical evidence from STEP-1 and SELECT trials and why structured care is essential.
5 min read
Cardiologist Sues UPMC; BP Control Stagnant; GLP-1 in Pregnancy
A prominent cardiologist has filed a whistleblower lawsuit against UPMC alleging racist texts and CEO conflicts. Meanwhile, U.S. blood pressure control remains below pre-pandemic levels, per new data. GLP-1 drugs during pregnancy show promising maternal benefits with no rise in fetal risks, according to a meta-analysis.
6 min read
Eli Lilly Turns to AI After GLP-1 Boom for Next Growth
Eli Lilly is leveraging artificial intelligence to find its next big breakthrough after the GLP-1 boom transformed diabetes and obesity treatment. With rivals like Novo Nordisk in hot pursuit, Lilly's AI investments promise faster drug discovery and smarter clinical trials. This strategic shift could diversify revenue and bring new options to patients sooner.
6 min read
ARD-201 Trial: Maintaining Weight Loss After Ozempic, Wegovy
GLP-1 drugs like Ozempic and Wegovy deliver impressive weight loss, but regain is common after stopping. A new Phase 2 trial of oral ARD-201 aims to change that by regulating appetite via bitter taste receptors. Led by obesity expert Lawrence Cheskin at George Mason University, this study targets post-treatment weight maintenance.
5 min read
Biomea Fusion Reports Positive Phase II Data for Diabetes Drug Icovamenib
Biomea Fusion has released promising Phase II data from the COVALENT-111 study, demonstrating icovamenib's ability to significantly reduce HbA1c levels in specific diabetes patient subgroups over 52 weeks. With no serious treatment-related adverse events and durable effects nine months post-dosing, this oral menin inhibitor could offer new options for metabolic disease management. Investors note positive stock momentum amid upcoming trials.
5 min read
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
CagriSema Falls Short vs. Tirzepatide in Obesity Drug Trial
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
5 min read
GLP-1s Show Promise in MS, But More Rigorous Research Needed
GLP-1 receptor agonists, originally developed for diabetes, are gaining attention for potential benefits in multiple sclerosis (MS) due to their effects on the brain and metabolic health. Expert Afsaneh Shirani, MD, highlighted promising studies at ACTRIMS, including weight loss and minimal relapses, but stressed the need for more rigorous trials. Key challenges like biomarkers, patient selection, and access remain.
6 min read
China Biotech Targets 2028 Trials for Semaglutide Nasal Spray Like Wegovy
A Shanghai-based biotech is developing a nasal spray version of semaglutide, the key ingredient in Novo Nordisk's Wegovy, with global clinical trials targeted for completion by 2028. This experimental weight-management spray promises lower costs than tablets and better suitability for long-term use. As Novo's patent nears expiration in China, competition heats up in the booming GLP-1 market.
4 min read
Tirzepatide vs Semaglutide: Weight Loss Duration After Stopping
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but what happens when you stop? Pivotal trials reveal significant regain risks, underscoring obesity as a chronic condition. This guide breaks down the evidence and offers practical insights for sustained results.
4 min read
Roche CT-388: 22.5% Weight Loss Tops Wegovy in Phase 2 Trial
Roche's experimental obesity drug CT-388 delivered impressive 22.5% average weight loss in a phase 2 trial, surpassing Novo Nordisk's Wegovy and rivaling Eli Lilly's Zepbound. Over half of participants resolved obesity by dropping below a BMI of 30. This positions Roche as a serious contender in the booming GLP-1 market.
4 min read
GLP-1 Receptor Agonists and Next-Generation Metabolic Hormone Therapies for Chronic Kidney Disease
Clinical trials across the cardiovascular-kidney-metabolic spectrum demonstrate kidney protective effects of incretin-based therapies. Multiple studies show GLP-1RAs and dual GIP/GLP-1RAs reduce kidney disease progression, albuminuria, and kidney failure risk in patients with type 2 diabetes and chronic kidney disease.
10 min read
Semaglutide Fails to Slow Alzheimer's Progression in Study
A recent clinical trial, Evoke, investigated semaglutide's potential to slow Alzheimer's disease. While the drug improved certain Alzheimer's-related biomarkers, it did not delay the disease's progression. Researchers emphasize the need for multi-faceted approaches to tackle Alzheimer's.
2 min read
Lilly Seeks FDA OK for Orforglipron, an Oral Weight Loss Drug | TechTarget
Eli Lilly has submitted orforglipron, its oral GLP-1 therapy, for FDA approval following successful phase 3 trial outcomes. The weight loss pill demonstrates promise in addressing weight regain issues often seen when patients discontinue GLP-1 therapy. The study showed patients maintained weight loss for up to a year.
3 min read
Eli Lilly's Stock Momentum Builds Amidst Positive Clinical Data and Institutional Backing
Eli Lilly & Co. is experiencing heightened market interest, fueled by significant institutional investor activity and promising clinical data. The convergence of these factors raises questions about the sustainability of the company's valuation in light of high expectations.
4 min read
MEOW-1 Trial Begins: Key Facts About the "Cat Ozempic"
OKAVA Pharmaceuticals has initiated a clinical trial to assess a weight loss treatment for obese cats using a GLP-1 implant. With a significant portion of cats in the U.S. being overweight, this trial marks a potential advancement in veterinary medicine.
3 min read
Clinical Trial Indicates Eli Lilly's 3-Target Drug Achieves New Weight Loss Milestone for Obesity
A novel drug candidate from Eli Lilly, targeting three metabolic pathways, has shown impressive weight loss results in a late-stage clinical trial. The study revealed an average weight loss of 28.7% among participants. However, the trial also reported a notable rate of treatment discontinuation.
3 min read
Semaglutide Fails to Slow Advancement of Alzheimer's Disease
Results from a recent trial indicate that semaglutide, typically used for obesity, did not slow the progression of Alzheimer's disease. While the drug improved Alzheimer's-related biomarkers, this did not translate to a delay in the disease's advancement. Researchers emphasize the need for multi-faceted approaches to tackle Alzheimer's.
2 min read
Novel GLP-1 Pill Demonstrates Potential for Weight Reduction
Research suggests a daily GLP-1 pill could be a promising option for weight management. The results indicate a potential alternative to injectable weight loss treatments. Health tracking apps like Shotlee can help monitor progress.
1 min read
Cardioprotection Comparison: GLP-1 Drugs Show Similar Effects
Research comparing tirzepatide and semaglutide shows both medications reduce the risk of major cardiovascular events. The study highlights the early onset of cardioprotective effects, suggesting mechanisms beyond just weight loss. These findings support the integration of both agents into cardiovascular clinical practice.
2 min read
Lilly's Eloralintide Obesity Drug Advances to Phase 3 Trials
Eli Lilly is progressing its experimental amylin obesity drug, eloralintide, into late-stage clinical trials following successful phase 2 study outcomes. The mid-stage study demonstrated significant weight loss in participants receiving the highest dose of the drug.
3 min read
Eli Lilly Advances Amylin Obesity Drug to Late-Stage Trials After Study Shows 20% Weight Reduction
Eli Lilly is set to begin late-stage trials for its investigational amylin obesity drug following promising mid-stage study results. The trial showed the highest dose of the weekly injection, eloralintide, resulted in an average weight loss of 20.1% in obese or overweight patients over 48 weeks.
3 min read
GLP-1 Breakthrough: Mazdutide Outperforms Semaglutide for Weight Loss & Diabetes
New research shows that Mazdutide may be superior to Semaglutide (Ozempic/Wegovy) for weight loss and improved blood sugar control. Learn about this exciting development and what it means for the future of diabetes and weight management.
3 min read